Abstract 782P
Background
CRS after neoadjuvant chemotherapy (NACT) and gBRCA status predict survival outcomes of women diagnosed with advanced HGSOC. We investigated the correlation between CRS and gBRCA to understand the potential of CRS as an inexpensive biomarker for PARPi therapy.
Methods
Analysis of the OC gBRCA testing database from a tertiary referral centre. Eligible criteria included women with FIGO stage IIIC/IV HGSOC who received NACT and had gBRCA tested between 01/09/2017 and 31/12/2022. Univariable and Multivariable (MV) Cox Proportional-Hazards Models were applied to assess the association between PFS, OS and clinical factors. Two-Proportions Z Test was applied to assess the proportions of CRS1+2 or CRS3 between gBRCA.
Results
536 women were eligible. Mean age 66 years (range 36–89). 139 had FIGO stage IVB HGSOC. 71% received 3-weekly carboplatin with paclitaxel. Median PFS was 14.4 months (95%CI 13.6–15.4) and OS 38.0 months (95%CI 34.8–42.6) in the overall population. Performance status (0–1 vs. 2–4), cytoreductive surgery (Yes vs. No) and gBRCA status (mutant[MT] vs. wild type[WT]) were predictive (PFS) and prognostic (OS) in the overall population (all P<0.05). 363 women underwent delayed primary surgery (DPS) and had a CRS. Of these, 90% received 3–4 cycles of NACT and 96% had optimal (≤1 cm) cytoreduction. In the NACT-DPS group, MV analysis showed that residual disease (≤1 vs. >1 cm), CRS (3 vs. 1+2) and gBRCA status (MT vs. WT) were predictive (PFS) (all P≤0.02). Proportion testing showed women with gBRCA2 were more likely to have CRS3 vs. CRS1+2 than those with gBRCA1 (P=0.008). Women with gBRCA1 (P=0.075) and gBRCA2 (P=0.078) were not more likely to have CRS3 vs. CRS1+2 then those with WT.
Conclusions
We found a correlation between CRS3 and gBRCA2, but not gBRCA1, in women with FIGO stage IIIC/IV HGSOC treated with NACT-DPS. CRS should be evaluated in a prospective study as a predictor of PARPi efficacy.
Table: 782P
CRS | gBRCA1 | gBRCA2 | WT | PFS, months (95%CI) |
1 | 7 | 1 | 60 | 12.1 (11.5–15.7) |
2 | 19 | 9 | 146 | 15.4 (14.4–16.7) |
1+2 | 26 (84%) | 10 (45%) | 206 (66%) | 14.9 (14.0–16.0) |
3 | 5 (16%) | 12 (55%) | 104 (34%) | 22.8 (20.7–27.9) |
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
R.D. Morgan.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
779P - Assessment of the RAD51 test to determine homologous recombination deficiency (HRD) in patients (pts) with newly diagnosed advanced high-grade epithelial ovarian cancer carcinoma (HGOC)
Presenter: Carmen Garcia Duran
Session: Poster session 11
780P - Role of BRCA1 promotor methylation in homologous recombination deficiency (HRD) in high-grade ovarian cancer
Presenter: Heidelinde Fiegl
Session: Poster session 11
781P - Chemotherapy sensitivity score based on ex vivo 3D tumour testing to predict clinical response for ovarian cancer patients
Presenter: Janneke Walraven
Session: Poster session 11
783P - The role of JARID1B in ovarian cancer
Presenter: Katharina Leitner
Session: Poster session 11
784P - HPV integration promotes HPV carcinogenesis via remodeling chromatin interactions between universal stripe factors and super-enhancer in HPV-related carcinoma
Presenter: Canhui Cao
Session: Poster session 11
785P - The predictive role of circulating exosomal PD-L1 in cervical cancer immunotherapy
Presenter: Wenjie Tang
Session: Poster session 11
786P - Antitumor activity of farletuzumab ecteribulin in a panel of endometrial cancer patient-derived xenografts with four different molecular subtypes
Presenter: Kosei Hasegawa
Session: Poster session 11
787P - A NGS panel for molecular classification of endometrial carcinoma
Presenter: Hao Wen
Session: Poster session 11
788P - Molecular profiling of p53 mutant endometrial cancer reveals distinct subgroups with opportunities for personalized therapeutic approaches
Presenter: Felix Blanc-Durand
Session: Poster session 11
789P - Real-world (RW) duration of treatment in first-line maintenance (1Lm) niraparib monotherapy in epithelial ovarian cancer (EOC): CHAR1ZMA study
Presenter: Floor Backes
Session: Poster session 11